Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin aspart-szjj
- Development stage
- Approved
- Lead developer
- Tonghua Dongbao
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Merilog (insulin aspart-szjj) is a rapid-acting human insulin analog biosimilar to NovoLog (insulin aspart), approved for improving glycemic control in adults and pediatric patients with diabetes mellitus. It is administered subcutaneously within 5–10 minutes before a meal and is available in both 10 mL multiple-dose vials and 3 mL single-patient-use prefilled pens. The mechanism of action involves increasing peripheral glucose uptake, especially by skeletal muscle and fat, while inhibiting hepatic glucose production. Clinical studies have demonstrated that Merilog provides noninferior glycemic control compared to the reference product with a similar safety profile[1][2][4][6].
- Brand names
- MerilogMerilog SoloStar
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin aspart-szjj.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin aspart-szjj.